Regulation - Research

Filter

Current filters:

Research

Popular Filters

76 to 100 of 318 results

Rigel sees clear forward path for fostamatinib but will drop R333

25-10-2013

Clinical-stage US drug developer Rigel Pharmaceuticals has announced mixed updates on two of its pipeline…

BiotechnologyDermatologicalsfostamatinibImmunologicalsR333RegulationResearchRigel Pharmaceuticals

Merck & Co expects to file BLA for HPV vaccine candidate V503 this year

Merck & Co expects to file BLA for HPV vaccine candidate V503 this year

25-10-2013

Merck & Co yesterday provided an overview of the clinical trial program for V503, the company’s investigational…

Merck & CoNorth AmericaPharmaceuticalRegulationResearchV503Vaccines

Ariad stops Ph III Iclusing trial on blood clot woes

18-10-2013

US biotech firm Ariad Pharmaceuticals’took another tumble, falling 35% to $2.91, as the company said…

Ariad PharmaceuticalsBiotechnologyIclusigNorth AmericaOncologyRegulationResearch

Oxford BioMedica gets US and French go-ahead to resume recruitment into ocular clinical trials

17-10-2013

Oxford BioMedica has received agreement from the US Food and Drug Administration and the French regulatory…

BiotechnologyEuropeOphthalmicsOxford BioMedicaRegulationResearch

Reliable assessment of drugs is only possible on the basis of clinical study reports, says IQWiG

Reliable assessment of drugs is only possible on the basis of clinical study reports, says IQWiG

11-10-2013

In 2012, researchers from the German Institute for Quality and Efficiency in Health Care (IQWiG) presented…

EuropePharmaceuticalRegulationResearch

Bioniche’s Canadian filing for Urocidin delayed

10-10-2013

Canadian biopharma firm Bioniche Life Sciences has provided an update on its plans for a New Drug Submission…

Bioniche Life SciencesLicensingPharmaceuticalRegulationResearchUrocidin

FDA clinical hold on Iclusig sees Ariad stock go into free-fall

FDA clinical hold on Iclusig sees Ariad stock go into free-fall

10-10-2013

US drugmaker Ariad Pharmaceuticals saw its shares plunge 59% to $6.99 yesterday, wiping $2 billion off…

Ariad PharmaceuticalsBiotechnologyIclusigNorth AmericaOncologyRegulationResearch

PhRMA calls for regulatory environment to support rare disease research

PhRMA calls for regulatory environment to support rare disease research

08-10-2013

US biopharmaceutical research companies are developing 452 new medicines for rare diseases, according…

North AmericaPharmaceuticalRare diseasesRegulationResearch

New data support GSK plan to file for approval of malaria vaccine in 2014

New data support GSK plan to file for approval of malaria vaccine in 2014

08-10-2013

Results from a large-scale Phase III trial, presented today at the Multilateral Initiative on Malaria…

GlaxoSmithKlinePharmaceuticalRegulationResearchRTS,STropical diseasesVaccines

Japanese lawmakers are stepping in to Diovan investigation

07-10-2013

Members of Japan’s Diet (Congressmen) have formed a bipartisan study group to examine Swiss drug major…

Asia-PacificCardio-vascularDiovanNovartisPharmaceuticalPoliticsRegulationResearch

Europe’s biopharma SMEs endorse further clinical data sharing but with reservations

04-10-2013

European Biopharmaceutical Enterprises, a specialized group of the EFPIA, says it recognizes the potential…

EuropePharmaceuticalRegulationResearch

EFPIA expresses serious concerns on EMA draft policy for clinical trials data

08-09-2013

Representing the research-based pharma industry in Europe, the European Federation of Pharmaceutical…

EuropePharmaceuticalRegulationResearch

Phase III data support biosimilarity of BOW-015 to Remicade

29-08-2013

Privately-held US biotech firm EPIRUS Biopharmaceuticals, which is focused on the development and production…

Anti-Arthritics/RheumaticsBiotechnologyEPIRUS BiopharmaceuticalsGenericsinfliximabRegulationRemicadeResearch

Positive results with MannKind's type 1 diabetes drug please investors

15-08-2013

There was good news for loss-making US drugmaker MannKind (Nasdaq: MNKD), when the company announced…

AfrezzaDiabetesMannKindNorth AmericaPharmaceuticalRegulationResearch

HAI Europe questions pharma commitment to clinical trial data transparency, claiming leaked documents suggest otherwise

29-07-2013

Consumer advocacy Health Action International (HAI) Europe says it welcomes any initiative that grants…

BiotechnologyEuropeNorth AmericaPharmaceuticalPoliticsRegulationResearch

Vertex slumps as FDA delays hepatitis C trial

26-07-2013

US drug maker Vertex Pharmaceuticals (Nasdaq: VRTX) saw its shares drop 11% to $78 a share, in after-hours…

Anti-viralsBiotechnologyNorth AmericaPharmaceuticalRegulationResearchVertexVX-135

US orphan designation for defactinib in mesothelioma

25-07-2013

US cancer drug developer Verastem (Nasdaq: VSTM) says that its lead cancer stem cell inhibitor, VS-6063…

BiotechnologydefactinibOncologyPharmaceuticalRegulationResearchVerastem

European and US drugmakers commit to responsible clinical data sharing

24-07-2013

In a joint statement issued this morning (July 24), the European Federation of Pharmaceutical Industries…

BiotechnologyEuropeNorth AmericaPharmaceuticalRegulationResearch

FDA grants orphan designation for Armagen's lead product

19-07-2013

California, USA-based Armagen says that the US Food and Drug Administration has granted orphan drug designation…

AGT-182ArmagenPharmaceuticalRare diseasesRegulationResearch

Annual approvals of new drugs for neglected diseases nearly doubled since early 2000s and 2009-12; Tufts

14-07-2013

The annual number of new drug approvals worldwide to treat neglected diseases has nearly doubled in recent…

Anti-viralsPharmaceuticalRegulationResearchTropical diseases

Celgene gets negative NICE view on Revlimid in rare blood cancer; presents new data in newly-diagnosed MM

11-07-2013

US biotech firm Celgene (Nasdaq: CELG) today (July 11) expressed disappointment at the preliminary decision…

BiotechnologyCelgeneEuropeOncologyPricingRare diseasesRegulationResearchRevlimid

The case for Insmed's CF drug candidate Arikace; analysts' views

05-07-2013

The 16% decline in US biotech firm Insmed's (Nasdaq CM: INSM) stock is an overreaction to results from…

ArikaceBiotechnologyFinancialInsmedRare diseasesRegulationResearchRespiratory and Pulmonary

76 to 100 of 318 results

Company Spotlight

ImmunoGen

ImmunoGen

Back to top